Picard Medical reports 85% YoY revenue growth, gross margin improvement to 28% in pre-annual meeting presentation

Picard Medical, Inc.

Revenue increased 85% YoY; US revenue up 116%; gross margin improved to 28% from year-end 2025.
Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.
Annual meeting on July 17, 2026; proposals include director elections, capital structure amendments, auditor ratification, exec comp advisory vote.
Interim CEO Richard Fang highlights business progress despite recent leadership changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.